| Autor | Jahr | Metastase/Rezidiv Östrogen-Rezeptor | |
| positiv | negativ | ||
| Hoehn (6) | 1979 | 13 | 0 |
| Brennan (7) | 1979 | 3 | 2 |
| Hull (8) | 1983 | 81 | 23 |
| Holdaway (9) | 1983 | 3 | 6 |
| Raemaekers (10) | 1984 | 35 | 8 |
| Nomura (11) | 1985 | 17 | 10 |
| Kamby (12) | 1989 | 16 | 24 |
| Spataro (13) | 1992 | 185 | 76 |
| Li (14) | 1994 | 50 | 13 |
| Kuukasjärvi (15) | 1996 | 23 | 12 |
| Shimizu (16) | 2000 | 5 | 5 |
| Sekido (17) | 2003 | 27 | 6 |
| Lower (18) | 2005 | 76 | 39 |
| Gutierrez (19) | 2005 | 24 | 5 |
| Gomez-Fernandez (20) | 2008 | 150 | 9 |
| Wu (21) | 2008 | 4 | 2 |
| Broom (22) | 2009 | 45 | 6 |
| Thompson (4) | 2010 | 98 | 11 |
| Idirisinghe (23) | 2010 | 62 | 12 |
| Hoefnagel (24) | 2010 | 130 | 17 |
| Gong (2) | 2011 | 147 | 10 |
| Bogina (25) | 2011 | 103 | 8 |
| Curigliano (26) | 2011 | 175 | 22 |
| Sari (27) | 2011 | 33 | 16 |
| Nishimura (28) | 2011 | 54 | 8 |
| Chang (29) | 2011 | 18 | 8 |
| Amir (5) | 2012 | 58 | 11 |
| Jensen (30) | 2012 | 85 | 10 |
| Montagna (31) | 2012 | 187 | 18 |
| Duchnowska (32) | 2012 | 29 | 22 |
| Lindstrom (33) | 2012 | 216 | 113 |
| Ibrahim (34) | 2013 | 76 | 11 |
| Dieci (35) | 2013 | 81 | 13 |
| Aurilio (36) | 2013 | 81 | 19 |
| Curtit (37) | 2013 | 164 | 29 |
| de Duenas (3) | 2014 | 108 | 16 |
| Summe | 2662 | 620 | |
| Prozent | 81,1% | 18,9% | |
Metastasen / Rezidive Östrogen-Rezeptor positiver Tumoren sind zu 4/5 ebenfalls Rezeptor positiv in 1/5 Rezeptor negativ.
| Autor | Jahr | Metastase/Rezidiv Östrogen-Rezeptor | |
| positiv | negativ | ||
| Hoehn (6) | 1979 | 7 | 17 |
| Brennan (7) | 1979 | 5 | 17 |
| Hull (8) | 1983 | 12 | 51 |
| Holdaway (9) | 1983 | 9 | 10 |
| Raemaekers (10) | 1984 | 6 | 26 |
| Nomura (11) | 1985 | 0 | 15 |
| Kamby (12) | 1989 | 2 | 50 |
| Spataro (13) | 1992 | 46 | 94 |
| Li (14) | 1994 | 11 | 9 |
| Kuukasjärvi (15) | 1996 | 0 | 15 |
| Shimizu (16) | 2000 | 0 | 10 |
| Sekido (17) | 2003 | 1 | 10 |
| Lower (18) | 2005 | 21 | 64 |
| Gutierrez (19) | 2005 | 0 | 10 |
| Gomez-Fernandez (20) | 2008 | 0 | 119 |
| Wu (21) | 2008 | 0 | 4 |
| Broom (22) | 2009 | 5 | 6 |
| Thompson (4) | 2010 | 3 | 25 |
| Idirisinghe (23) | 2010 | 7 | 36 |
| Hoefnagel (24) | 2010 | 7 | 79 |
| Gong (2) | 2011 | 7 | 63 |
| Bogina (25) | 2011 | 1 | 28 |
| Curigliano (26) | 2011 | 15 | 43 |
| Sari (27) | 2011 | 11 | 15 |
| Nishimura (28) | 2011 | 2 | 33 |
| Chang (29) | 2011 | 9 | 21 |
| Amir (5) | 2012 | 4 | 21 |
| Jensen (30) | 2012 | 4 | 19 |
| Montagna (31) | 2012 | 7 | 70 |
| Duchnowska (32) | 2012 | 13 | 56 |
| Lindstrom (33) | 2012 | 36 | 94 |
| Ibrahim (34) | 2013 | 8 | 21 |
| Dieci (35) | 2013 | 3 | 22 |
| Aurilio (36) | 2013 | 3 | 4 |
| Curtit (37) | 2013 | 11 | 31 |
| de Duenas (3) | 2014 | 5 | 38 |
| Summe | 281 | 1212 | |
| Prozent | 18,8% | 81,2% | |
Metatasen / Rezidive Östrogen-Rezeptor negativer Tumoren sind zu 4/5 ebenfalls Rezeptor negativ in 1/5 Rezeptor positiv.
| Autor | Jahr | Metastase/Rezidiv Progesteron-Rezeptor | |
| positiv | negativ | ||
| Holdaway (9) | 1983 | 1 | 4 |
| Raemaekers (10) | 1984 | 13 | 10 |
| Li (14) | 1994 | 10 | 8 |
| Kuukasjärvi (15) | 1996 | 18 | 12 |
| Shimizu (16) | 2000 | 6 | 6 |
| Sekido (17) | 2003 | 16 | 8 |
| Lower (18) | 2005 | 34 | 59 |
| Wu (21) | 2008 | 3 | 2 |
| Broom (22) | 2009 | 24 | 22 |
| Thompson (4) | 2010 | 63 | 22 |
| Idirisinghe (23) | 2010 | 33 | 37 |
| Hoefnagel (24) | 2010 | 71 | 58 |
| Bogina (25) | 2011 | 66 | 25 |
| Curigliano (26) | 2011 | 58 | 106 |
| Sari (27) | 2011 | 22 | 26 |
| Nishimura (28) | 2011 | 36 | 19 |
| Chang (29) | 2011 | 11 | 10 |
| Amir (5) | 2012 | 12 | 34 |
| Montagna (31) | 2012 | 112 | 46 |
| Duchnowska (32) | 2012 | 18 | 23 |
| Lindstrom (33) | 2012 | 109 | 142 |
| Ibrahim (34) | 2013 | 24 | 38 |
| Dieci (35) | 2013 | 36 | 36 |
| Aurilio (36) | 2013 | 43 | 43 |
| Curtit (37) | 2013 | 98 | 52 |
| de Duenas (3) | 2014 | 86 | 34 |
| Summe | 1023 | 882 | |
| Prozent | 53,7% | 46,3% | |
Metastasen / Rezidive Progesteron-Rezeptor positiver Tumoren sind nur zur Häfte Rezeptor positiv in knapp der Hälfte Rezeptor negativ.
| Autor | Jahr | Metastase/Rezidiv Progesteron-Rezeptor | |
| positiv | negativ | ||
| Holdaway (9) | 1983 | 3 | 12 |
| Raemaekers (10) | 1984 | 4 | 23 |
| Li (14) | 1994 | 6 | 8 |
| Kuukasjärvi (15) | 1996 | 0 | 20 |
| Shimizu (16) | 2000 | 0 | 8 |
| Sekido (17) | 2003 | 2 | 18 |
| Lower (18) | 2005 | 9 | 71 |
| Wu (21) | 2008 | 0 | 4 |
| Broom (22) | 2009 | 0 | 13 |
| Thompson (4) | 2010 | 12 | 40 |
| Idirisinghe (23) | 2010 | 8 | 43 |
| Hoefnagel (24) | 2010 | 12 | 92 |
| Bogina (25) | 2011 | 5 | 44 |
| Curigliano (26) | 2011 | 18 | 73 |
| Sari (27) | 2011 | 13 | 11 |
| Nishimura (28) | 2011 | 6 | 36 |
| Chang (29) | 2011 | 4 | 31 |
| Amir (5) | 2012 | 4 | 44 |
| Montagna (31) | 2012 | 16 | 105 |
| Duchnowska (32) | 2012 | 11 | 67 |
| Lindstrom (33) | 2012 | 33 | 146 |
| Ibrahim (34) | 2013 | 10 | 43 |
| Dieci (35) | 2013 | 10 | 36 |
| Aurilio (36) | 2013 | 4 | 17 |
| Curtit (37) | 2013 | 17 | 68 |
| de Duenas (3) | 2014 | 13 | 34 |
| Summe | 220 | 1107 | |
| Prozent | 16,6% | 83,4% | |
Metastasen / Rezidive Progesteron-Rezeptor negativer Tumoren sind zu 5/6 auch Rezeptor negativ in 1/6 Rezeptor positiv.
Discordance in hormon receptor status among primary, metastatic, and second primary breast cancers. Biological difference or misclassification?
The Oncologist 19(2014):592-601
2. Gong Y, Han EY, Guo M et al.:
Stability of estrogen receptor Status in breast Carcinoma: A comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy.
Cancer 117(2011):705-713
3. de Duenas EM, Hernändez AL, Zotano AG et al.:
Prospective evaluation of the conversion rate in the receptor Status between primary breast Cancer and metastasis: Results from the GEICAM 2009-03 ConvertHER study.
Breast Cancer Res Treat 143(2014):507-515
4.Thompson AM, Jordan LB, Quinlan P et al.:
Prospective comparison of Switches in biomarker Status between primary and recurrent breast Cancer: The Breast Recurrence In Tissues Study (BRITS).
Breast Cancer Res 12(2010):R92
5. Amir E, Miller N, Geddie W et al.:
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast Cancer.
J Clin Oncol 30(2012):587-592
6. Hoehn JL, Plotka ED, Dickson KB:
Comparison of estrogen receptor levels in primary and regional metastatic Carcinoma of the breast.
Ann Surg 190(1979):69-71
7. Brennan MJ, Donegan WL, Appleby DE:
The variability of estrogen receptors in metastatic breast Cancer.
Am J Surg 137(1979):260-262
8. Hull DF, Clark GM, Osborne CK et al.:
Multiple estrogen receptor assays in human breast Cancer.
Cancer Res 43(1983):413-416
9. Holdaway IM, Bowditch JV:
Variation in receptor Status between primary and metastatic breast Cancer.
Cancer 52(1983):479-485
10. Raemaekers JM, Beex LV, Koenders AJ et al.:
Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast Cancer: Relation to survival.
Eur J Cancer Clin Oncol 20(1984):1011-1018
11. Nomura Y,Tashiro H, Shinozuka K.:
Changes of Steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast Cancer.
Cancer 55(1985):546-551
12. Kamby C, Rasmussen BB, Kristensen B:
Oestrogen receptor Status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence.
Br J Cancer 60(1989):252-257
13. Spataro V, Price K, Goldhirsch A et al.:
Sequential estrogen receptor determinations from primary breast Cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group).
Ann Oncol 3(1992):733-740
14. Li BD, Byskosh A, Molteni A et al.:
Estrogen and progesterone receptor concordance between primary and recurrent breast Cancer.
J Surg Oncol 57(1994):71-77
15. Kuukasjärvi T, Kononen J, Heiin H et al.:
Loss of estrogen receptor in recurrent breast Cancer is associated with poor response to endocrine therapy.
J Clin Oncol 14(1996):2584-2589
16. Shimizu C, Fukutomi T, Tsuda H et al.:
c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast Cancer tissues.
J Surg Oncol 73(2000):17-20
17. Sekido Y, Umemura S, Takekoshi S et al.:
Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent Sites: HER2 gene amplification and p53 mutation.
Int J Oncol 22(2003):1225-1232
18. Lower EE, Glass EL, Bradley DA et al.:
Impact of metastatic estrogen receptor and progesterone receptor Status on survival.
Breast Cancer Res Treat 90(2005):65-70
19. Gutierrez MC, Detre S, Johnston S et al.:
Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
J Clin Oncol 23(2005):2469-2476
20. Gomez-Fernandez C, Daneshbod Y, Nassiri M et al.:
Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer.
Am J Clin Pathol 130(2008): 879-882
21. Wu JM, Fackler MJ, Halushka MK et al.:
Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and Promoter methylation between primary tumors and their multifocal metastases.
Clin Cancer Res 14(2008):1938-1946
22. Broom RJ,Tang PA, Simmons C et al.:
Changes in estrogen receptor, progesterone receptor and Her-2/neu Status with time: Discordance rates between primary and metastatic breast cancer.
Anticancer Res 29(2009):1557-1562
23. Idirisinghe PK, Thike AA, Cheok PY et al.:
Hormone receptor and C-ERBB2 Status in distant metastatic and locally recurrent breast cancer. Pathologie correlations and clinical significance.
Am J Clin Pathol 133(2010):416-429
24. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al.:
Receptor conversion in distant breast cancer metastases.
Breast Cancer Res 12(2010):R75
25. Bogina G, Bortesi L, Marconi M et al.:
Compar-ison of hormonal receptor and her-2 Status between breast primary tumours and relapsing tumours: Clinical implications of progesterone receptor loss.
Virchows Arch 459(2011):1-10
26. Curigliano G, Bagnardi V, Viale G et al.
Should liver metastases of breast cancer be biopsied to improve treatment choice?
Ann Oncol 22(2011):2227-2233
27. Sari E, Guler G, Hayran M et al.:
Comparative study of the immunohistochemical detection of hormone receptor Status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.
Med Oncol 28(2011):57-63
28. Nishimura R, Osako T, Okumura Y et al.:
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: Discordance rates and prognosis.
World J Surg Oncol 9(2011):131
29. Chang HJ, Han SW, Oh DY et al.:
Discordant human epidermal growth factor receptor 2 and hormone receptor Status in primary and metastatic breast cancer and response to trastuzumab.
Jpn J Clin Oncol 41(2011):593-599
30. Jensen JD, Knoop A, Ewertz M et al.:
ER, HER2, and TOP2A expression in primary tumor, synchro-nous axillary nodes, and asynchronous metastases in breast cancer.
Breast Cancer Res Treat 132(2012): 511-521
31. Montagna E, Bagnardi V, Rotmensz N et al.:
Breast cancer Subtypes and outcome after local and regional relapse.
Ann Oncol 23(2012):324-331
32. Duchnowska R, Dziadziuszko R, Trojanowski T et al.:
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastasesto the brain.
Breast Cancer Res 14(2012):R119
33. Lindstrom LS, Karlsson E, Wilking UM et al.:
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are un-stable throughout tumor progression.
J Clin Oncol 30(2012):2601-2608
34. Ibrahim T, Farolfi A, Scarpi E et al.:
Hormonal receptor, human epidermal growth factor reeeptor-2, and Ki67 discordance between primary breast cancer and paired metastases:
Clinical impact. Oncology 84(2013):150-157
35. Dieci MV, Barbieri E, Piacentini F et al.:
Discordance in receptor Status between primary and recurrent breast cancer has a prognostic impact: A single-institution analysis.
Ann Oncol 24(2013): 101-108
36. Aurilio G, Monfardini L, Rizzo S et al.:
Discordant hormone receptor and human epidermal growth factor receptor 2 Status in bone metastases compared to primary breast cancer.
Acta Oncol 52(2013):1649-1656
37. Curtit E, Nerich V, Mansi L et al.:
Discordances in estrogen receptor Status, progesterone receptor Status, and HER2 Status between primary breast cancer and metastasis.
The Oncologist 18(2013):667-674
